Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

Abstract: The present invention is concerned with compounds inhibiting CD95 signaling in pancreatic cancer cells. Furthermore, contemplated by the current invention are medicaments comprising such a compound for the prevention and/or treatment of pancreatic cancer as well as the use of such a compound for the manufacture of a medicament for the prevention and/or treatment of pancreatic cancer, the prevention of migration of cancer cells, and/or the prevention and/or treatment of an inflammatory reaction. The present invention also refers to a method for the identification of a compound inhibiting CD95 signaling, as we to a method for the manufacture of a medicament comprising the steps of the method for the identification of a compound inhibiting CD95 signaling and the further step of formulating the inhibiting compound as a medicament.

Abstract: The present invention is concerned with compounds inhibiting CD95 signaling in pancreatic cancer cells. Furthermore, contemplated by the current invention are medicaments comprising such a compound for the prevention and/or treatment of pancreatic cancer as well as the use of such a compound for the manufacture of a medicament for the prevention and/or treatment of pancreatic cancer, the prevention of migration of cancer cells, and/or the prevention and/or treatment of an inflammatory reaction. The present invention also refers to a method for the identification of a compound inhibiting CD95 signaling, as we to a method for the manufacture of a medicament comprising the steps of the method for the identification of a compound inhibiting CD95 signaling and the further step of formulating the inhibiting compound as a medicament.

Abstract: The present invention relates to the activation of the CD95L/CD95 system for inducing neuronal differentiation in vitro and in vivo and the use of CD95L compositions to effect differentiation.

Abstract: The present invention relates to methods for treating an individual with high grade glioblastoma multiforme by preventing or disrupting the binding of CD95 to its ligand, CD95L, in vivo, whereupon that neutralization of CD95 activity reduces undesirable glial cell migration and invasion into body tissue.

Abstract: The present invention relates to the use of GD3 synthase inhibitors for treating neuropathological disorders, in particular cerebral ischemia, traumatic damage to the brain and spinal cord, and neurodegenerative disorders, and signs, symptoms and dysfunctions associated therewith, and to a method for the preparation of pharmaceuticals for the treatment of neuropathological disorders.